Preoperative ketorolac to prevent recurrence of lung cancer in patients with operable disease

Preoperative ketorolac to prevent recurrence of lung cancer in patients with operable disease
Description: 

Lung cancer is sometimes diagnosed in its early stages. Surgery, with or without adjuvant/neoadjuvant radiation and/or chemotherapy is used depending on stage of the disease. However, these tumors often recur within the first few years and lead to death.

One theory for these early recurrences is that that the body’s response to the tissue injury caused by surgery is to secrete a number of growth factors and cytokines important for tissue repair. Unfortunately, these effects can also cause microclusters of tumor cells lodged in distant locations to start growing and eventually form macroscopic metastases. Thus, a short term intervention that reduces the perioperative inflammatory response may reduce recurrence and increase survival.

Anesthesiologists can choose different drugs during surgery, including non-steroidal anti-inflammatory drugs (NSAIDs). A recent study found that in patients with non-small cell lung cancer (NSCLC) undergoing surgery for stage I and II disease, an intraoperative dose of the NSAID ketorolac or diclofenac showed a tendency to increase metastasis free survival (p value 0.07) over 10 years by about 15% in absolute levels. This is a retrospective study from one center. The proposal now is to conduct a randomized prospective trial: operable lung cancer patients will be treated either with or without ketorolac just prior to surgery and recurrences and overall survival will be monitored.

Cost: 
$300,000 - $500,000
Impact: 
If successful, this simple, one-time, affordable, and non-toxic intervention could save approximately 7,000 lives a year annually in the US alone. In healthcare costs, over a half a billion dollars a year would be saved. Contact GlobalCures at (781) 269 - 2602 if you would like to Fund this trial.